39 reports of this reaction
4.4% of all ISOPROTERENOL HYDROCHLORIDE reports
#2 most reported adverse reaction
TORSADE DE POINTES is the #2 most commonly reported adverse reaction for ISOPROTERENOL HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 39 FDA adverse event reports linking ISOPROTERENOL HYDROCHLORIDE to TORSADE DE POINTES. This represents approximately 4.4% of all 894 adverse event reports for this drug.
Patients taking ISOPROTERENOL HYDROCHLORIDE who experience torsade de pointes should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TORSADE DE POINTES is moderately reported among ISOPROTERENOL HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to torsade de pointes, the following adverse reactions have been reported for ISOPROTERENOL HYDROCHLORIDE:
TORSADE DE POINTES has been reported as an adverse event in 39 FDA reports for ISOPROTERENOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TORSADE DE POINTES accounts for approximately 4.4% of all adverse event reports for ISOPROTERENOL HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience torsade de pointes while taking ISOPROTERENOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.